Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis

REFERENCES

1. 1.↵
   1. Mease PJ

   . Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis 2011;70 Suppl 1:i77–84.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Rudwaleit M,
   2. van der Heijde D,
   3. Landewé R,
   4. Listing J,
   5. Akkoc N,
   6. Brandt J,
   7. et al.

   The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777–83.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Chandran V,
   2. Raychaudhuri SP

   . Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010;34:314–21.

   OpenUrlCrossRef
4. 4.↵
   1. Costa L,
   2. Caso F,
   3. D’Elia L,
   4. Atteno M,
   5. Peluso R,
   6. Del Puente A,
   7. et al.

   Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 2012;31:711–5.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Ritchlin CT,
   2. Kavanaugh A,
   3. Gladman DD,
   4. Mease PJ,
   5. Helliwell P,
   6. Boehncke WH,
   7. et al;
   8. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

   . Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387–94.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Gossec L,
   2. Smolen JS,
   3. Gaujoux-Viala C,
   4. Ash Z,
   5. Marzo-Ortega H,
   6. van der Heijde D,
   7. et al.

   European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4–12.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Mease PJ

   . Psoriatic arthritis treatment update. Bull NYU Hosp Jt Dis 2012;70:167–71.

   OpenUrlPubMed
8. 7a.↵
   1. Cohen JD

   . Successful treatment of psoriatic arthritis with rituximab. Ann Rheum Dis 2008;67:1647–8.

   OpenUrlFREE Full Text
9. 8.↵
   1. Kingsley GH,
   2. Kowalczyk A,
   3. Taylor H,
   4. Ibrahim F,
   5. Packham JC,
   6. McHugh NJ,
   7. et al.

   A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368–77.

   OpenUrlAbstract/FREE Full Text
10. 9.↵
    1. Atzeni F,
    2. Sarzi-Puttini P,
    3. Vena G

    . Resistant cases of psoriatic arthritis: how to manage them. J Rheumatol Suppl. 2009 Aug;83:73–5.

    OpenUrlAbstract/FREE Full Text
11. 10.↵
    1. Tak PP,
    2. Kalden JR

    . Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011;13 Suppl 1:S5.

    OpenUrlPubMed
12. 11.↵
    1. Atzeni F,
    2. Ventura D,
    3. Batticciotto A,
    4. Boccassini L,
    5. Sarzi-Puttini P

    . Interleukin 6 blockade: tocilizumab in psoriatic arthritis. J Rheumatol Suppl. 2012 Jul;89:97–9.

    OpenUrlAbstract/FREE Full Text
13. 12.↵
    1. Elkayam O,
    2. Jiries N,
    3. Dranitzki Z,
    4. Kivity S,
    5. Lidar M,
    6. Levy O,
    7. et al.

    Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol 2014;41:244–7.

    OpenUrlAbstract/FREE Full Text
14. 13.↵
    1. Caso F,
    2. Iaccarino L,
    3. Bettio S,
    4. Ometto F,
    5. Costa L,
    6. Punzi L,
    7. et al.

    Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab. Immunol Res 2013;56:390–7.

    OpenUrlPubMed
15. 14.↵
    1. Ogata A,
    2. Umegaki N,
    3. Katayama I,
    4. Kumanogoh A,
    5. Tanaka T

    . Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 2012;79:85–7.

    OpenUrlCrossRefPubMed
16. 15.↵
    1. Hughes M,
    2. Chinoy H

    . Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology 2013;52:1728–9.

    OpenUrlFREE Full Text
17. 16.↵
    1. Costa L,
    2. Caso F,
    3. Cantarini L,
    4. Del Puente A,
    5. Scarpa R,
    6. Atteno M

    . Efficacy of tocilizumab in a patient with refractory psoriatic arthritis. Clin Rheumatol 2014;33:1355–7.

    OpenUrlCrossRefPubMed
18. 17.↵
    1. McKeage K

    . Ustekinumab: a review of its use in psoriatic arthritis. Drugs 2014;74:1029–39.

    OpenUrlCrossRefPubMed
19. 18.↵
    1. Weitz JE,
    2. Ritchlin CT

    . Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. Expert Opin Biol Ther 2014;14:515–26.

    OpenUrlPubMed
20. 19.↵
    1. Fiocco U,
    2. Accordi B,
    3. Martini V,
    4. Oliviero F,
    5. Facco M,
    6. Cabrelle A,
    7. et al.

    JAK/STAT/PKCθ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res 2014;58:61–9.

    OpenUrlCrossRefPubMed
21. 20.↵
    1. Mazur M,
    2. Karczewski J,
    3. Lodyga M,
    4. Zaba R,
    5. Adamski Z

    . Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis. J Dermatolog Treat 2014 Dec 29 (E-pub ahead of print).